Results 191 to 200 of about 1,150,155 (343)

CLDN18.2 CAR‐derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer

open access: yesAdvanced Healthcare Materials, EarlyView.
CLDN18.2 CAR‐T cell‐derived small extracellular vesicles (CAR‐sEVs) display potent cytotoxicity and prolong survival in preclinical pancreatic cancer models. They contain functional CAR proteins and granzyme B, exhibit antigen specificity, and effectively target tumor cells while sparing healthy cells.
Yue Qing   +7 more
wiley   +1 more source

Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response

open access: yesAdvanced Healthcare Materials, EarlyView.
In this paper, a novel nanoparticle scaffold composed of dendrimers conjugated with peptide‐based immune checkpoint inhibitors, enhancing drug delivery efficacy is introduced. By conjugating PD‐L1‐binding peptides to dendrimers, multivalent binding effects are harnessed, resulting in enhanced binding affinity, prolonged half‐life, and improved ...
DaWon Kim   +11 more
wiley   +1 more source

Immunosuppressive Formulations for Immunological Defense against Traumatic Brain Injury

open access: yesAdvanced Healthcare Materials, EarlyView.
A novel subcutaneous formulation combining alpha‐ketoglutarate, glycolysis inhibitor PFK15, and a myelin peptide reduces inflammation in a mouse TBI model. This formulation promotes regulatory immune cells, enhances autophagy, and improves motor function, suggesting its potential as a prophylactic immunosuppressive therapy to mitigate TBI‐induced ...
Kelly Lintecum   +28 more
wiley   +1 more source

Induction of idiotype-specific suppressor T cells with antigen/antibody complexes. [PDF]

open access: bronze, 1983
Michael J. Caulfield   +3 more
openalex   +1 more source

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

open access: yesAdvanced Materials, EarlyView.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy